Two-signal models are useful in explaining various types of immune responses. In particular, secondary, so-called costimulatory, signals are critically required for the process of T-cell activation, survival, differentiation, and memory formation. Early studies in rodent models showed that targeting T-cell costimulatory pathways elicits immunological tolerance, providing a basis for development of costimulatory therapeutics in allograft rejection. However, as the classic definition of T-cell costimulation continues to evolve, simple blockade of costimulatory pathways has limitations in prevention of allograft rejection. Furthermore, functions of costimulatory molecules are much more diverse than initially anticipated and beyond T cells. In this mini-review, we will discuss CD137-CD137L bidirectional signals as examples showing that two-signals can be applicable to multiple phases of immune responses.
INTRODUCTION
Two-signal models have helped shape our understanding of T-cell activation for over 40 years (1) . T cells specifically recognize antigens through their surface T-cell receptor (TCR) in the context of MHC-peptide complexes. This signal (signal 1) can fully activate T cells only when signal 2, also known as a costimulatory signal, is provided. This paradigm of T cell activation shed light on the area of immunotherapy, since blocking costimulatory signaling pathways at the time of antigen encounter was shown to result in an antigen-specific T-cell tolerance. Consequently great efforts were exerted to reduce alloreactive or autoreactive T cells during autoimmunity or transplantation using this approach. Now, one fruit of these efforts, a blocker of a prototype of costimulatory molecules called CTLA-4-Ig, was translated into the clinic (2) . In the mean, as our understanding of costimulation has evolved considerably, its concept has been more broadly used and simple blockade of costimulatory pathways has had its limitations in clinical applications. First, it now become clear that costimulation blockade acts on multiple phases of immune response and its mechanisms of action involve not only clonal deletion but also regulation (3, 4) . Second, costimulation blockade has shown to be insufficient to induce allograft tolerance in non-human primates due to high frequency of memory T cells that are less dependent upon conventional costim-ulation for their activation (5) (6) (7) (8) (9) (10) . Finally, the classical two-signal model is now being modified due to existence of numerous costimulatory molecules with a diversity of functions (11, 12) . To make the story more complex, spatiotemporal expression of costimulatory receptor and their ligand(s) are continuously influenced by dynamic environmental conditions, making combinations of cell surface interaction more complex (12) . In addition multiple pairing of receptor and ligand molecules and the existence of bidirectional signaling indicate that more complex combinations of signaling events occur after receptor-ligand interactions.
Two-signal models exist in a variety of forms and provide a frame for activation of innate immunity cells as well as T cells (12, 13) . In this case, signal 1 is pattern recognition receptors (PRRs), antibody receptors, and molecules expressed in stressed cells. Signal 2 is provided by molecules belonging to many molecular families, including T-cell costimulatory receptors or ligands. The requirement for two signals is thought to be evolutionally conserved in the immune system because it acts as a safeguard that regulates the powerful and potentially harmful immune reaction and prevents the accidental triggering of responses against the host's own tissues (13) . In this mini-review, we will discuss costimulatory network during immune responses, focusing on CD137-CD137L bidirectional signals as an example.
T-CELL COSTIMULATION
CD137 is a member of the TNF receptor family and its expression is inducible in T cells (14, 15) . Induction of CD137 can be triggered by TCR signaling and CD28 signaling further increases TCR-mediated upregulation of CD137 expression, suggesting that CD137 signaling is dependent upon CD28 signaling (16) . Nonetheless, CD137 is thought to have distinct roles in T-cell-mediated immune responses.
Either blocking the CD137 signaling pathway using gene deletion/blockers or stimulating it using agonist antibodies is widely adopted to exploit CD137 functions. Even though it is believed that CD137 cooperates with so many other cos- 
TWO-SIGNAL ACTIVATION OF INNATE RESPONSES
Observations showing that lower extents of inflammatory diseases occur in CD137-deficient mice or mice treated with CD137 blockers are considered to be evidence for the in- There are few reports on roles of CD137L signaling in disease context. As mentioned above, CD137L signaling is indispensible for ischemia-reperfusion kidney injury (43) .
Considering that CD137L signaling is critical in inflammatory responses, it is predicted that milder inflammatory diseases will occur in the absence of CD137L signals.
Indeed, we showed that blocking of CD137L can inhibit in- 
CD137-CD137L BIDIRECTIONAL SIGNALS AS AN INTEGRATOR OF INNATE AND ADAPTIVE IMMUNITY
Now it is clear that CD137 and CD137L provide a cos- Accumulating is evidence indicating that CD137L signaling is a convergence point for inflammation. CD137L signaling is particularly a good target for ischemia-reperfusion renal injury. Blocking the CD137L signaling pathway may turn out to be effective in chronic allograft rejection.
However, it should be clearly defined before clinical applications of CD137 or CD137L-related reagents how immune networks involving CD137-CD137L bidirectional signaling determine pathophysiological environments.
